African-American, Hispanic men less likely to get treatment for prostate cancer, even with high-risk disease
Page 1 of 1
African-American, Hispanic men less likely to get treatment for prostate cancer, even with high-risk disease
African-American, Hispanic men less likely to get treatment for prostate cancer, even with high-risk disease
African-American and Hispanic men in the United States are less likely to receive therapy for prostate cancer compared to Caucasian men -- even when they have more aggressive disease, according to new research from Roswell Park Cancer Institute and Vanderbilt University Medical Center. The study, senior authored by Willie Underwood, III, MD, MPH, MSci, of Roswell Park, has been published online ahead of print in the journal Urology.
"Despite their higher risk for more aggressive disease, African-American men and Hispanic men are less likely to receive treatment, and less treatment may play a significant role in increased rates of death from prostate cancer," says Dr. Underwood, the paper's senior author and Associate Professor in the Department of Urology at Roswell Park. "This research demonstrates a need for an action plan to address a racial disparity that has been known for more than 20 years."
The study was based on data for 327,641 men diagnosed with localized prostate cancer between 2004 and 2011, as reported to the national Surveillance, Epidemiology and End Results (SEER) Program. The researchers evaluated factors including race, age, treatment, Gleason score, marital status, year of diagnosis, D'Amico risk classification and whether or not the men received definitive treatment.
The researchers concluded that African-American men and Hispanic men were less likely to receive therapy compared to Caucasian and Asian-American men, even when they had high risk prostate cancers (Gleason score of 7 or higher). It is possible that many of these men had opted to defer treatment while continuing in the care of medical professionals, an approach known as watchful waiting or active surveillance.
They also analyzed the data using the D'Amico risk model, which calculates the risk of recurrence following localized treatment for prostate cancer. The analysis reveals that African-American men diagnosed within each category -- low-, intermediate- and high-risk disease -- had significantly lower odds of receiving definitive treatment. Hispanic men with intermediate- or high-risk disease also had lower odds of receiving treatment.
More: https://www.sciencedaily.com/releases/2016/10/161007221714.htm
African-American and Hispanic men in the United States are less likely to receive therapy for prostate cancer compared to Caucasian men -- even when they have more aggressive disease, according to new research from Roswell Park Cancer Institute and Vanderbilt University Medical Center. The study, senior authored by Willie Underwood, III, MD, MPH, MSci, of Roswell Park, has been published online ahead of print in the journal Urology.
"Despite their higher risk for more aggressive disease, African-American men and Hispanic men are less likely to receive treatment, and less treatment may play a significant role in increased rates of death from prostate cancer," says Dr. Underwood, the paper's senior author and Associate Professor in the Department of Urology at Roswell Park. "This research demonstrates a need for an action plan to address a racial disparity that has been known for more than 20 years."
The study was based on data for 327,641 men diagnosed with localized prostate cancer between 2004 and 2011, as reported to the national Surveillance, Epidemiology and End Results (SEER) Program. The researchers evaluated factors including race, age, treatment, Gleason score, marital status, year of diagnosis, D'Amico risk classification and whether or not the men received definitive treatment.
The researchers concluded that African-American men and Hispanic men were less likely to receive therapy compared to Caucasian and Asian-American men, even when they had high risk prostate cancers (Gleason score of 7 or higher). It is possible that many of these men had opted to defer treatment while continuing in the care of medical professionals, an approach known as watchful waiting or active surveillance.
They also analyzed the data using the D'Amico risk model, which calculates the risk of recurrence following localized treatment for prostate cancer. The analysis reveals that African-American men diagnosed within each category -- low-, intermediate- and high-risk disease -- had significantly lower odds of receiving definitive treatment. Hispanic men with intermediate- or high-risk disease also had lower odds of receiving treatment.
More: https://www.sciencedaily.com/releases/2016/10/161007221714.htm
eddie- King of Beards. Keeper of the Whip. Top Chef. BEES!!!!!! Mushroom muncher. Spider aficionado!
- Posts : 43129
Join date : 2013-07-28
Age : 25
Location : England
Similar topics
» ‘Proton Therapy’ is Noninvasive Treatment for High-Risk Cancers – In Use Today With ‘Excellent’ Success Rate
» Prostate cancer set to become most common form of disease, with half of cases diagnosed late
» New data reveals how Hispanic voters could decide the next American president
» Migraines could be an immune system disease, opening up new treatment paths
» Cheese Actually Reduces Risk of Cardiovascular Disease and Provides a Lot of Health Benefits
» Prostate cancer set to become most common form of disease, with half of cases diagnosed late
» New data reveals how Hispanic voters could decide the next American president
» Migraines could be an immune system disease, opening up new treatment paths
» Cheese Actually Reduces Risk of Cardiovascular Disease and Provides a Lot of Health Benefits
Page 1 of 1
Permissions in this forum:
You cannot reply to topics in this forum
Sat Mar 18, 2023 12:28 pm by Ben Reilly
» TOTAL MADNESS Great British Railway Journeys among shows flagged by counter terror scheme ‘for encouraging far-right sympathies
Wed Feb 22, 2023 5:14 pm by Tommy Monk
» Interesting COVID figures
Tue Feb 21, 2023 5:00 am by Tommy Monk
» HAPPY CHRISTMAS.
Sun Jan 01, 2023 7:33 pm by Tommy Monk
» The Fight Over Climate Change is Over (The Greenies Won!)
Thu Dec 15, 2022 3:59 pm by Tommy Monk
» Trump supporter murders wife, kills family dog, shoots daughter
Mon Dec 12, 2022 1:21 am by 'Wolfie
» Quill
Thu Oct 20, 2022 10:28 pm by Tommy Monk
» Algerian Woman under investigation for torture and murder of French girl, 12, whose body was found in plastic case in Paris
Thu Oct 20, 2022 10:04 pm by Tommy Monk
» Wind turbines cool down the Earth (edited with better video link)
Sun Oct 16, 2022 9:19 am by Ben Reilly
» Saying goodbye to our Queen.
Sun Sep 25, 2022 9:02 pm by Maddog
» PHEW.
Sat Sep 17, 2022 6:33 pm by Syl
» And here's some more enrichment...
Thu Sep 15, 2022 3:46 pm by Ben Reilly
» John F Kennedy Assassination
Thu Sep 15, 2022 3:40 pm by Ben Reilly
» Where is everyone lately...?
Thu Sep 15, 2022 3:33 pm by Ben Reilly
» London violence over the weekend...
Mon Sep 05, 2022 2:19 pm by Tommy Monk
» Why should anyone believe anything that Mo Farah says...!?
Wed Jul 13, 2022 1:44 am by Tommy Monk
» Liverpool Labour defends mayor role poll after turnout was only 3% and they say they will push ahead with the option that was least preferred!!!
Mon Jul 11, 2022 1:11 pm by Tommy Monk
» Labour leader Keir Stammer can't answer the simple question of whether a woman has a penis or not...
Mon Jul 11, 2022 3:58 am by Tommy Monk
» More evidence of remoaners still trying to overturn Brexit... and this is a conservative MP who should be drummed out of the party and out of parliament!
Sun Jul 10, 2022 10:50 pm by Tommy Monk
» R Kelly 30 years, Ghislaine Maxwell 20 years... but here in UK...
Fri Jul 08, 2022 5:31 pm by Original Quill